Eli Lilly and Co (LLY)
746.20
-40.03
(-5.09%)
USD |
NYSE |
Nov 15, 16:00
746.24
+0.04
(+0.01%)
Pre-Market: 20:00
Eli Lilly Research and Development Expense (TTM): 10.53B for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 10.53B |
| June 30, 2024 | 10.21B |
| March 31, 2024 | 9.851B |
| December 31, 2023 | 9.313B |
| September 30, 2023 | 8.747B |
| June 30, 2023 | 8.140B |
| March 31, 2023 | 7.566B |
| December 31, 2022 | 7.191B |
| September 30, 2022 | 7.093B |
| June 30, 2022 | 6.996B |
| March 31, 2022 | 6.869B |
| December 31, 2021 | 6.931B |
| September 30, 2021 | 6.870B |
| June 30, 2021 | 6.630B |
| March 31, 2021 | 6.366B |
| December 31, 2020 | 6.086B |
| September 30, 2020 | 5.829B |
| June 30, 2020 | 5.745B |
| March 31, 2020 | 5.757B |
| December 31, 2019 | 5.595B |
| September 30, 2019 | 5.405B |
| June 30, 2019 | 5.305B |
| March 31, 2019 | 5.174B |
| December 31, 2018 | 5.051B |
| September 30, 2018 | 4.885B |
| Date | Value |
|---|---|
| June 30, 2018 | 4.944B |
| March 31, 2018 | 4.945B |
| December 31, 2017 | 5.096B |
| September 30, 2017 | 5.387B |
| June 30, 2017 | 5.284B |
| March 31, 2017 | 5.348B |
| December 31, 2016 | 5.310B |
| September 30, 2016 | 5.238B |
| June 30, 2016 | 5.144B |
| March 31, 2016 | 4.978B |
| December 31, 2015 | 4.796B |
| September 30, 2015 | 4.538B |
| June 30, 2015 | 4.638B |
| March 31, 2015 | 4.664B |
| December 31, 2014 | 4.734B |
| September 30, 2014 | 5.023B |
| June 30, 2014 | 5.158B |
| March 31, 2014 | 5.292B |
| December 31, 2013 | 5.531B |
| September 30, 2013 | 5.519B |
| June 30, 2013 | 5.484B |
| March 31, 2013 | 5.475B |
| December 31, 2012 | 5.278B |
| September 30, 2012 | 5.170B |
| June 30, 2012 | 5.108B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
5.595B
Minimum
Dec 2019
10.53B
Maximum
Sep 2024
7.416B
Average
6.963B
Median
Research and Development Expense (TTM) Benchmarks
| Amgen Inc | 5.774B |
| Biogen Inc | 2.080B |
| Johnson & Johnson | 16.41B |
| Viking Therapeutics Inc | 91.16M |
| Moderna Inc | 4.827B |